When Diagnostic Hypotheses Fail: Lessons in Cancer Care

Clinical analysis of diagnostic and treatment failures in oncology. Real cases of false-positive results and overdiagnosis. For physicians.

When Brilliant Hypotheses Crash Against Reality: What Failures in Cancer Diagnosis and Treatment Teach Us When Brilliant Hypotheses Crash Against Reality: What Failures in Cancer Diagnosis and Treatment Teach Us Andrey Viktorovich, 68 years old, a former design engineer, sits in my office with an expression I've learned to recognize over years of oncology practice. This isn't fear of diagnosis—he received that three months ago. This is the disappointment of someone who trusted "the most modern methods," underwent expensive diagnostics, and now learns that the results were false positive. His PSA rose to 8.2 ng/ml after radical prostatectomy performed two years ago for prostatic adenocarcinoma with Gleason score 7 (3+4). Pelvic MRI showed nothing. So we referred him for an "innovative" study—SPECT/CT with [99mTc]Tc-PSMA, a modality that in recent years has been presented as a breakthrough in imaging prostate cancer recurrence. The result was positive: two foci of radiopharmaceutical uptake in pelvic lymph nodes. We began planning radiation therapy. But Andrey Viktorovich is a meticulous person; he insisted on CT-guided biopsy. Histology showed reactive hyperplasia of lymphoid tissue. No cancer. How many such cases do we miss? How many patients receive unnecessary treatment based on false signals? Oncology is experiencing an era of rapid technological development. Each year brings new diagnostic methods, targeted drugs, immunotherapeutic agents. Scientific journals are filled with reports of "revolutionary achievements" and "breakthroughs." However, behind the glossy facade of successes lies a less attractive reality: many promising approaches fail to meet expectations in clinical practice. Drugs that showed impressive efficacy in mouse models fail in clinical trials. Diagnostic tests with high sensitivity demonstrate unacceptably low specificity. Combinations that worked in small pilot studies don't confirm their effect in large randomized controlled trials. Why does this happen? It's not just that cancer biology is more complex than we thought—though this is certainly true. The problem runs deeper: modern oncology has developed a culture that encourages publication of positive results and silencing of failures. Publication bias leads to negative studies remaining in desk drawers or at best being published in obscure journals. Meanwhile, analysis of failures often provides more valuable information than description of another success. When we understand why something doesn't work, we move closer to understanding the true mechanisms of disease. Andrey Viktorovich's case is not an exception but a typical example of a systemic problem. A meta-analysis conducted by Domenico Albano and colleagues showed that the detection rate of prostate cancer recurrence using [99mTc]Tc-PSMA SPECT/CT varies widely, and the method's specificity is far from ideal. But this is rarely mentioned in diagnostic center marketing materials. Similarly, we observe cases of severe immunotherapy complications that lead to death—for example, hemophagocytic lymphohistiocytosis described in rare clinical observations—but the frequency of such events in real practice may be higher than in registration studies. In this article, I want to examine several areas of oncology practice through the lens of failures and negative results. We'll discuss why new diagnostic methods don't always work as promised; why cancer finds ways to bypass the most sophisticated therapeutic strategies; why regulatory agencies increasingly reject applications for anticancer drug registration; and why supportive therapy that seems harmless may prove ineffective or even harmful. I'll examine each of these topics through specific clinical cases, because it's in the stories of real patients that the true complexity of oncology practice manifests. False Promises of Molecular Imaging: When Sensitivity Becomes a Curse Let's return to Andrey Viktorovich and his false-positive PSMA scan. To understand why this happened, we need to examine the method's principles. Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein expressed on prostate cancer cell surfaces. With disease progression and metastasis appearance, PSMA expression usually increases, making it an attractive imaging target. Radiopharmaceuticals labeled with technetium-99m or gallium-68 bind to PSMA and allow detection of even small foci of tumor tissue. Sounds perfect. The problem is that PSMA is expressed not only in prostate cancer cells. It's present in endothelium of newly formed vessels of various tumors, in proximal tubule cells of kidneys, in ganglion cells, in salivary glands. Moreover, inflammatory processes can induce PSMA expression in lymph nodes. This is probably what happened with Andrey Viktorovich: a local inflammatory process in pelvic lymph nodes (possibly a consequence of previous surgery and radiation therapy to the prostate bed) led to radiopharmaceutical accumulation. A systematic review and meta-analysis by Albano, including data from multiple studies, showed that the detection rate of recurrence using [99mTc]Tc-PSMA SPECT/CT depends on many factors. At PSA levels below 0.5 ng/ml, the method's sensitivity is about 40-50%, at PSA from 0.5 to 1.0 ng/ml—about 60%, and only at PSA above 2.0 ng/ml does it reach 75-80%. This means that at low PSA values, when clinicians most need imaging to make treatment decisions, the method often doesn't help. But another aspect is even more important: the method's specificity in various studies ranged from 75% to 95%, meaning that in 5-25% of cases we see false-positive results. Five to twenty-five percent—is that a lot or a little? Let's calculate. If a large cancer center performs 500 PSMA scans per year in patients with suspected prostate cancer recurrence, and 200 of them actually have recurrence (prevalence 40%, which is realistic), then with 85% specificity we'll get 45 false-positive results per year. Forty-five…
All research articles Research digest Physician article feed